DIHOMO-GAMMA-LINOLENIC ACID


Synonyms	.gamma.-homolinolenic acid 20:3 (.omega.-6) fatty acid 20:3(N-6) 8z,11z,14z-eicosatrienoic acid Bishomo-.gamma.-linolenic acid Cis-8,11,14-Eicosatrienoicacid DS-107G DS107G Daleuton Dihomo-.gamma.-linolenic acid Dihomo-gamma-linolenic acid Diroleuton Ds-107 Ds107 RO 12-1989
Status
Molecule Category	UNKNOWN
UNII	FC398RK06S


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	HOBAELRKJCKHQD-QNEBEIHSSA-N
Smiles	CCCCC/C=C\C/C=C\C/C=C\CCCCCCC(=O)O
InChI	InChI=1S/C20H34O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20(21)22/h6-7,9-10,12-13H,2-5,8,11,14-19H2,1H3,(H,21,22)/b7-6-,10-9-,13-12-

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C20H34O2
Molecular Weight	306.49
AlogP	6.44
Hydrogen Bond Acceptor	1.0
Hydrogen Bond Donor	1.0
Number of Rotational Bond	15.0
Polar Surface Area	37.3
Molecular species	ACID
Aromatic Rings	0.0
Heavy Atoms	22.0

Related Entries

Cross References

Resources	Reference
ChEBI	53486
ChEMBL	CHEMBL465183
DrugBank	DB00154
FDA SRS	FC398RK06S
Human Metabolome Database	HMDB0002925
Guide to Pharmacology	9775
KEGG	C03242
PDB	LAX
PharmGKB	PA164743249
SureChEMBL	SCHEMBL842729
ZINC	ZINC000004521470

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).